Biogen Inc. Files 8-K for Financial Results

TL;DR

Biogen dropped its Q1 2026 financials on 8-K today.

AI Summary

Biogen Inc. filed an 8-K report on April 6, 2026, to disclose its results of operations and financial condition. The filing includes various XBRL documents detailing financial information, such as schema, label, and presentation linkbases, along with an extracted XBRL instance document and an iXBRL 8-K.

Why It Matters

This filing provides crucial, up-to-date financial information for Biogen Inc., allowing investors and analysts to assess the company's performance and make informed decisions.

Risk Assessment

Risk Level: low — This is a routine filing of financial results, not indicating any unusual or significant risks.

Key Players & Entities

• BIOGEN INC. (company) — Filer of the 8-K report
• 0000875045 (company) — CIK number for Biogen Inc.
• 2026-04-06 (date) — Filing date and period of report

FAQ

Key Financial Figures

• $0.0005 — ange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Select
• $34 million — and milestone expense of approximately $34 million on a pre-tax basis. The estimated charg
• $0.19 — first quarter of 2026 by approximately $0.19 per share. Acquired in-process resear

Filing Documents

• biib-20260406.htm (8-K) — 24KB
• biib-20260406_g1.jpg (GRAPHIC) — 3KB
• 0000875045-26-000039.txt ( ) — 197KB
• biib-20260406.xsd (EX-101.SCH) — 2KB
• biib-20260406_lab.xml (EX-101.LAB) — 21KB
• biib-20260406_pre.xml (EX-101.PRE) — 24KB
• biib-20260406_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the first quarter of 2026 by approximately $0.19 per share. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development. Biogen does not forecast such acquired in-process research and development, upfront and milestone expense due to the uncertainty of the future occurrence, magnitude and timing of these transactions in any given period. Results for the quarter ended March 31, 2026, have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from the preliminary unaudited estimates described herein. Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements relating to our financial and operating results and financial guidance, that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the "Safe Harbor" provisions of the PSLRA. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "outlook," "plan," "possible," "potential," "predict," "project," "should," "target," "will," "would" or the negative of these

Signatures

Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biogen Inc. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: April 6, 2026

View Full Filing

View this 8-K filing on SEC EDGAR